IS THE WRITING ON THE WALL BIG ENOUGH YET? NEXT STEP RE TODAYS EXPANSION..... WHAT PRODUCER ARE THEY GONNA GOBBLE UP???
The Company will further develop its current cannabinoid product line, which includes capsules, tinctures, transdermal patches, spray, oils, water and topicals, into a full spectrum offering with both whole plant extracts and THC-only products. Whole plant extracts is a term used to describe products that include THC, CBD and other natural cannabis derivatives. The company will continue to externally source the cultivation of the plant and bring the manufacturing, processing, product R&D and distribution in-house.
“The launch of IsoLabs is a significant milestone for the company,” said Marcos Agramont, CEO of Isodiol. “We have had a presence in hemp derived, non-THC pharmaceutical and nutraceutical space for many years where we pioneered some of the first hemp derived products and technologies in the market. This strategic entrance into the licensed medical marijuana market will further expand our existing product lines. Also, as we continue to navigate the legal landscape in the US and Canada, having the ability to vertically integrate our operations is extremely important, which will be a strategy consistent throughout our international expansion.”
Currently, IsoLabs is exploring opportunities in the California and Canadian markets. For more information on Isodiol, please visit www.isodiol.com
Read more at https://www.stockhouse.com/news/press-releases/2017/09/28/isodiol-international-inc-announces-formation-of-isolabs-plans-to-expand-with#mqCZXFv6OsLMsCxT.99